<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159959" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Liraglutide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cerillo</surname>
            <given-names>John L.</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>John Cerillo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159959.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Liraglutide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA).&#x000a0;This drug&#x000a0;belongs to a class of antidiabetic agents called incretin mimetics. Incretins are endogenous compounds that improve glycemic control when&#x000a0;absorbed into the bloodstream. The FDA first approved liraglutide in 2010 as an adjunct treatment for type 2 diabetes (T2D) to improve glycemic control, in 2014 for chronic weight management in adults, and again in 2020 for pediatric patients aged 12 and older with obesity.<xref ref-type="bibr" rid="article-159959.r1">[1]</xref> As a monotherapy, liraglutide has been shown to reduce HbA1c levels up to 1.14%.<xref ref-type="bibr" rid="article-159959.r2">[2]</xref>&#x000a0;Liraglutide acts on the pancreatic &#x003b2;-cells to release endogenous insulin while also acting on appetite regulation centers in the brain to decrease appetite.<xref ref-type="bibr" rid="article-159959.r3">[3]</xref>&#x000a0;One study reported patients receiving liraglutide therapy lost an average of 18.5 lbs (8.4 kg).<xref ref-type="bibr" rid="article-159959.r4">[4]</xref></p>
        <p>The American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) Obesity Clinical Practice Guidelines suggest that patients with obesity should be offered chronic treatment using weight loss medications and lifestyle modifications, provided that the potential benefits outweigh the risks of adverse reactions. Liraglutide&#x000a0;is generally not recommended&#x000a0;as short-term therapy as this treatment duration&#x000a0;is not associated with&#x000a0;long-term health benefits.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Liraglutide administration is indicated for patients with T2D aged 10 or&#x000a0;older.&#x000a0;This drug also improves glycemic control while reducing major cardiovascular events in adults with T2D or established cardiovascular disease.</p>
        <p>Administration of liraglutide for weight loss is indicated&#x000a0;for the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults with a body mass index (BMI) &#x02265;30 kg/m<sup>2</sup></p>
          </list-item>
          <list-item>
            <p>Adults with a BMI &#x02265;27 kg/m<sup>2</sup> with at least one comorbid condition&#x000a0;(eg, hypertension, T2D, dyslipidemia)</p>
          </list-item>
          <list-item>
            <p>Children aged 12 or older with&#x000a0;an initial BMI &#x0003e;30 kg/m<sup>2</sup>&#x000a0;and weighing&#x000a0;at least&#x000a0;60 kg&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Liraglutide&#x000a0;has also been shown to reduce the risk of non-fatal cardiovascular (CV) events (ie, non-fatal myocardial infarction or non-fatal stroke) and CV mortality in adults with T2D and&#x000a0;CV disease.<xref ref-type="bibr" rid="article-159959.r5">[5]</xref>&#x000a0;Per the American Association of Clinical Endocrinology Clinical Practice Guideline for nonalcoholic fatty liver disease, liraglutide may be used as an alternative to semaglutide in patients with histologic evidence of nonalcoholic steatohepatitis and a BMI &#x0003e;27 kg/m<sup>2</sup> or comorbid T2D.<xref ref-type="bibr" rid="article-159959.r6">[6]</xref></p>
      </sec>
      <sec id="article-159959.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Liraglutide is a human glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 97% amino acid sequence homology to endogenous GLP-1. Liraglutide binds to GLP-1 receptors in the pancreatic &#x003b2;-cells, increasing intracellular cyclic AMP (cAMP) and&#x000a0;triggering&#x000a0;endogenous insulin release.<xref ref-type="bibr" rid="article-159959.r7">[7]</xref>&#x000a0;Insulin reduces blood glucose levels to reach euglycemia. GLP-1 receptor binding also leads to appetite suppression and&#x000a0;decreased caloric intake.<xref ref-type="bibr" rid="article-159959.r3">[3]</xref> In addition to&#x000a0;enhancing insulin secretion, acute liraglutide treatment has been shown to suppress glucagon secretion and promote &#x003b2;-cell proliferation.<xref ref-type="bibr" rid="article-159959.r8">[8]</xref><xref ref-type="bibr" rid="article-159959.r9">[9]</xref><bold>&#x000a0;</bold>No elevations in insulin secretion or glucagon secretion suppression&#x000a0;have been&#x000a0;observed at normal or low glucose concentrations&#x000a0;in patients receiving liraglutide therapy.<bold>&#x000a0;</bold></p>
        <p>GLP-1 receptors are found in several brain areas&#x000a0;associated with&#x000a0;appetite regulation, and endogenous GLP-1 regulates appetite and caloric intake.<xref ref-type="bibr" rid="article-159959.r1">[1]</xref><bold>&#x000a0;</bold>Liraglutide has been shown to exert anorexigenic effects by increasing free leptin levels, thus&#x000a0;reducing appetite.<xref ref-type="bibr" rid="article-159959.r10">[10]</xref>&#x000a0;Although the precise mechanism remains unclear, studies have demonstrated that liraglutide modulates brain activity in several regions.<xref ref-type="bibr" rid="article-159959.r11">[11]</xref>&#x000a0;The drug's&#x000a0;unique amino acid sequence confers resistance to degradation by dipeptidyl peptidase 4 (DPP-4) and neutral endopeptidase (NEP), prolonging its pharmacological activity.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Liraglutide is absorbed into the bloodstream after subcutaneous injection. Peak concentration is achieved between 8 and 12 hours. The absolute bioavailability&#x000a0;of liraglutide injection is 55%, and its maximum concentration increases proportionally&#x000a0;with&#x000a0;dose. There is no significant difference in absorption&#x000a0;between an injection in the upper arm and abdomen. However, injection in the thigh&#x000a0;may cause a 22% reduction in absorption.</p>
        <p><bold>Distribution:&#x000a0;</bold>Liraglutide is almost entirely bound to plasma proteins (&#x0003e;98%). The approximate volume of distribution after a subcutaneous injection of 0.6 mg is 13 L. After intravenous administration, the mean volume of distribution is 0.07 L/kg.</p>
        <p><bold>Metabolism:&#x000a0;</bold>Liraglutide is not metabolized by a specific organ; plasma protein degradation pathways endogenously metabolize it.&#x000a0;The plasma half-life of liraglutide is 13 hours after injection.<xref ref-type="bibr" rid="article-159959.r12">[12]</xref></p>
        <p><bold>Elimination:&#x000a0;</bold>Liraglutide is excreted through urine and feces. Studies have shown no trace of intact liraglutide in urine or feces.&#x000a0;Partially-degraded liraglutide was found in urine and feces at 6% and 5%, respectively.<xref ref-type="bibr" rid="article-159959.r13">[13]</xref></p>
      </sec>
      <sec id="article-159959.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Liraglutide is available&#x000a0;in a prefilled pen&#x000a0;containing&#x000a0;3 mL of a clear and colorless 6 mg/mL solution. This solution may be injected subcutaneously into the abdomen, thigh, or upper arm. Solutions containing&#x000a0;1.2 mg, 1.8 mg, and 3 mg are also available, though the injection dose may vary based on indication and age.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>For glycemic control:</bold>&#x000a0;The recommended adult dose for glycemic control is 1.2 mg daily. Patients should start with an initial dose of 0.6 mg daily for the first week and increase to 1.2 mg daily at the beginning of week 2. Increasing the dose to 1.8 mg daily may be necessary if glucose levels remain uncontrolled. An outline of dosing for glycemic control is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Week 1: 0.6 mg daily</p>
          </list-item>
          <list-item>
            <p>Week 2: 1.2 mg daily (if necessary)</p>
          </list-item>
          <list-item>
            <p>Week 3: 1.8 mg daily (if necessary)</p>
          </list-item>
        </list>
        <p><bold>For weight loss:&#x000a0;</bold>The recommended adult dose is 3 mg daily. Patients should start with an initial dose of 0.6 mg daily for&#x000a0;the first week&#x000a0;and increase the dose by 0.6 mg every week until the target dose of 3 mg is achieved. An outline of the dosing schedule for weight loss is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Week 1: 0.6 mg daily</p>
          </list-item>
          <list-item>
            <p>Week 2: 1.2 mg daily</p>
          </list-item>
          <list-item>
            <p>Week 3: 1.8 mg daily</p>
          </list-item>
          <list-item>
            <p>Week 4: 2.4 mg daily</p>
          </list-item>
          <list-item>
            <p>Week 5+: 3 mg daily</p>
          </list-item>
        </list>
        <p>If a dose is missed,&#x000a0;another should not be administered&#x000a0;immediately. Patients should wait for the next scheduled injection and continue with regular dosing. If more than 3 days of injections have been missed, patients should reinitiate treatment at 0.6 mg daily and follow the original titration information used when therapy was initiated.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Patient with hepatic impairment:&#x000a0;</bold>The safety and efficacy of liraglutide in patients with hepatic impairment have not been established. Patients should be closely monitored.</p>
        <p><bold>Patient with renal impairment:&#x000a0;</bold>The safety and efficacy of liraglutide have not been&#x000a0;established in patients with renal impairment. However, postmarketing surveillance has shown that acute renal failure and worsening of chronic renal failure have been reported in patients taking liraglutide. Patients with renal impairment should be closely&#x000a0;monitored while taking liraglutide.</p>
        <p><bold>Pregnancy:&#x000a0;</bold>Liraglutide (for glycemic control) should be used with caution during pregnancy. Animal studies have shown that liraglutide&#x000a0;is associated with an increased risk of fetal death and fetal abnormalities.<xref ref-type="bibr" rid="article-159959.r14">[14]</xref>&#x000a0;However, poorly controlled diabetes increases the morbidity and mortality of both the mother and the fetus during pregnancy.&#x000a0;Clinicians should administer liraglutide based on the patient's glycemic control. According to the American Diabetes Association, alternate medicines are preferred over liraglutide for patients who are pregnant.<xref ref-type="bibr" rid="article-159959.r15">[15]</xref> Liraglutide should never be used for weight loss during pregnancy.</p>
        <p><bold>Breastfeeding:&#x000a0;</bold>Liraglutide is safe for breastfeeding mothers. In clinical studies, liraglutide was not detected in human milk.<xref ref-type="bibr" rid="article-159959.r16">[16]</xref>&#x000a0;However, it was detected in the milk of rats at 50% of the maternal plasma concentration.</p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Liraglutide is safe for children aged 10 and older for glycemic control&#x000a0;and children aged 12 and older for weight loss.<xref ref-type="bibr" rid="article-159959.r17">[17]</xref>&#x000a0;Pediatric patients should be administered liraglutide for glycemic control according to the&#x000a0;same dosing schedule as adults.&#x000a0;Adequate control may be established&#x000a0;by administering 0.6 mg daily; these patients should be closely monitored.&#x000a0;Pediatric dosing for weight loss is the same as adult dosing. If a dose increase is not tolerated, the patient should remain at the lower dose for&#x000a0;another week and attempt to increase the following week. To increase the dose to 3 mg after consecutive weeks, a target dose of 2.4 mg daily is sufficient. Clinical trials showed that&#x000a0;liraglutide increased the risk of hypoglycemia and resting heart rate by 3 to 7 beats per minute in pediatric patients. Liraglutide has not been studied in children&#x000a0;younger than&#x000a0;10 years old.</p>
        <p><bold>Older patients:&#x000a0;</bold>Liraglutide is safe for use in patients 65&#x000a0;and older. Clinical studies have shown that using liraglutide in these populations does not increase the risk of adverse effects or decrease the effectiveness of the drug.<xref ref-type="bibr" rid="article-159959.r12">[12]</xref></p>
      </sec>
      <sec id="article-159959.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse reactions&#x000a0;associated with liraglutide administration&#x000a0;include nausea, diarrhea, vomiting, decreased appetite, dyspepsia, and constipation. Immunogenic-related events&#x000a0;have been reported in less than 0.8% of patients.</p>
        <p>The most severe adverse effects include the following<bold>:</bold></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Risk of C-cell tumors:</bold> Reports of patients developing medullary thyroid cancer (MTC) and C-cell tumors have been documented. Animal studies showed that liraglutide causes dose-&#x000a0;and duration-dependent thyroid C-cell tumors in mice and rats of both sexes.<xref ref-type="bibr" rid="article-159959.r18">[18]</xref>&#x000a0;Patients with a personal or family history of MTC or C-cell tumors should avoid liraglutide.<xref ref-type="bibr" rid="article-159959.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Acute pancreatitis:</bold>&#x000a0;Pancreatitis is a rare but&#x000a0;severe adverse effect.&#x000a0;Fewer than 0.4% of patients&#x000a0;experience pancreatitis. If pancreatitis is suspected, patients should stop injections immediately, call their doctor, and seek emergency care.<xref ref-type="bibr" rid="article-159959.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Acute gallbladder disease:</bold>&#x000a0;Cholelithiasis, or &#x0201c;gallstones,&#x0201d; is&#x000a0;a rare but urgent side effect of liraglutide injection. This adverse effect was&#x000a0;observed in 2.2% of patients. If symptoms of gallstone disease arise (eg, pain in the right upper quadrant after meals),&#x000a0;patients should&#x000a0;stop injections immediately, call their doctor, and seek emergency care.<xref ref-type="bibr" rid="article-159959.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Hypoglycemia:</bold>&#x000a0;The risk of hypoglycemia is&#x000a0;elevated&#x000a0;in patients&#x000a0;receiving liraglutide with other diabetic medications, including insulin or insulin secretagogues (eg, sulfonylureas). Symptoms of hypoglycemia include sweating, shaking, and dizziness.<xref ref-type="bibr" rid="article-159959.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Elevated&#x000a0;heart rate:</bold>&#x000a0;Liraglutide may increase the resting heart rate&#x000a0;by 4&#x000a0;to 9 bpm. Reports of heart rates exceeding 100 bpm have been documented.<xref ref-type="bibr" rid="article-159959.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Renal impairment:</bold> Liraglutide may cause acute renal failure or exacerbate kidney decline in patients with chronic renal failure. Reports of patients&#x02019; renal function declining to the point of dialysis have been documented. Patients with a history of&#x000a0;kidney disease should discuss the risks and benefits of starting liraglutide with their physician.<xref ref-type="bibr" rid="article-159959.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Hypersensitivity reactions:</bold> Anaphylaxis and angioedema have been reported during the use of liraglutide. If a patient experiences acute-onset breathing difficulties, hives, or swelling in the face or hands, they should immediately seek emergency medical care.<xref ref-type="bibr" rid="article-159959.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Suicidal behavior and ideation:</bold>&#x000a0;Suicidal thoughts and behaviors were reported in 0.3% of&#x000a0;patients during clinical studies. Liraglutide should not be administered to patients with a history of suicidal thoughts or behaviors, which may be exacerbated.&#x000a0;Suicidal thoughts&#x000a0;were increased in pediatric patients receiving liraglutide, amounting to 0.8% of the patients.<xref ref-type="bibr" rid="article-159959.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Absorption of oral medications may be affected due to delayed gastric emptying.</p>
          </list-item>
          <list-item>
            <p>Liraglutide has limited potential for interactions with drugs that utilize the cytochrome P450 system or plasma-binding proteins.</p>
          </list-item>
          <list-item>
            <p>Drugs administered concomitantly with liraglutide:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p><bold>Digoxin (1 mg):</bold> The area&#x000a0;under the curve (AUC) was reduced by 16%, and the maximum concentration (Cmax) was reduced by 31%.</p>
              </list-item>
              <list-item>
                <p><bold>Lisinopril (20 mg):</bold> The AUC was reduced by 15%, and the Cmax was&#x000a0;reduced&#x000a0;by 27%.</p>
              </list-item>
              <list-item>
                <p><bold>Atorvastatin (40 mg):</bold> The AUC was unchanged, and the Cmax was reduced by 38%.</p>
              </list-item>
              <list-item>
                <p><bold>Acetaminophen (1000 mg):</bold> The AUC was unchanged, and the Cmax was reduced by 31%.</p>
              </list-item>
              <list-item>
                <p><bold>Griseofulvin (500 mg):</bold> The AUC was unchanged, and the Cmax was increased by 37%.</p>
              </list-item>
              <list-item>
                <p><bold>Oral contraceptives (0.03 mg ethinylestradiol/0.15 mg levonorgestrel):</bold> The AUC was unchanged for ethinylestradiol and was increased by 18% for levonorgestrel; the Cmax was&#x000a0;reduced&#x000a0;for both drugs by&#x000a0;approximately 12%.</p>
              </list-item>
              <list-item>
                <p><bold>Insulin:</bold> No change in concentration has been observed. However, the hypoglycemic effects&#x000a0;may be enhanced, so clinicians should consider reducing the dose of liraglutide.</p>
              </list-item>
            </list>
          </list-item>
        </list>
      </sec>
      <sec id="article-159959.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Liraglutide has been shown to cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in rats and mice of both sexes. It is unknown whether liraglutide causes thyroid C-cell tumors, including MTC, in humans, as&#x000a0;the human relevance of liraglutide-induced rodent thyroid&#x000a0;C-cell tumors has not been determined.</p>
        <p>Liraglutide is contraindicated in patients with, or with a family history of,&#x000a0;MTC or MEN2.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Liraglutide should not be combined with insulin as&#x000a0;a mixture for injection.</p>
      </sec>
      <sec id="article-159959.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The patient's thyroid function and symptoms are monitored closely. Thyroid abnormalities (eg, nodules, dysphagia, dyspnea, hoarseness, new neck masses) should be investigated immediately. Serum calcitonin levels or a neck ultrasound are performed in such cases.&#x000a0;Clinicians should regularly assess plasma glucose levels, heart rate, renal function, changes in behavior, suicidal thoughts or behavior, worsening depression, triglycerides, signs and symptoms of pancreatitis, signs and symptoms of gallbladder disease, and body weight (if receiving liraglutide for chronic weight management). The patient's HbA1c levels should be obtained quarterly in patients whose treatment goals have not been met or with any change in medicines. HbA1c levels should be obtained at least twice a year in patients with stable glycemic control&#x000a0;who are meeting treatment goals.</p>
      </sec>
      <sec id="article-159959.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Severe nausea, vomiting, or hypoglycemia may indicate an overdose of liraglutide, which is treated with symptom management. There is no rescue drug for a liraglutide overdose.</p>
      </sec>
      <sec id="article-159959.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diagnosing and treating type 2 diabetes requires&#x000a0;regular collaboration within the healthcare team. Prescribers and pharmacists work together to ensure patients receive their medication at a reasonable cost and within an appropriate time frame. Continuous monitoring of patients' glucose levels assesses the effect of liraglutide on glycemic control. Primary care physicians and advanced-level providers diagnose and treat T2D and manage weight loss. In severe cases where glycemic control is not achieved with first- or second-line treatments, an endocrinologist may be consulted to further evaluate the patient's endocrine dysfunction. For weight loss, patients may require medications such as liraglutide to increase metabolism and reduce appetite. Pharmacists and prescribers communicate with patients to navigate insurance challenges, explore patient assistance programs, and consider alternative payment options to improve access to these medications. Nurses ensure patients understand safe and precise dose administration and drug interactions and educate patients on lifestyle and diet modifications when indicated. Patients taking liraglutide&#x000a0;should&#x000a0;follow up with their providers every 3 to 6 months to evaluate glycemic control or weight loss progress. Patients with diabetes require&#x000a0;close surveillance due to severe complications such as irreversible diabetic neuropathy. Patients taking liraglutide maintain regular appointments and monitor their blood glucose levels. Clinicians, pharmacists, and dieticians work collaboratively to ensure optimal use of liraglutide&#x000a0;to treat obesity and T2D.</p>
      </sec>
      <sec id="article-159959.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159959&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159959">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159959/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159959">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159959.s10">
        <title>References</title>
        <ref id="article-159959.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandfon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eylon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>e46623</fpage>
            <pub-id pub-id-type="pmid">37937009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garcia-Hernandez</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Rodriguez-Pattzi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Olvera-Alvarez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Zdravkovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bode</surname>
                <given-names>B</given-names>
              </name>
              <collab>LEAD-3 (Mono) Study Group</collab>
            </person-group>
            <article-title>Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.</article-title>
            <source>Lancet</source>
            <year>2009</year>
            <month>Feb</month>
            <day>07</day>
            <volume>373</volume>
            <issue>9662</issue>
            <fpage>473</fpage>
            <page-range>473-81</page-range>
            <pub-id pub-id-type="pmid">18819705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Secher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jelsing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baquero</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Hecksher-S&#x000f8;rensen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cowley</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dalb&#x000f8;ge</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grove</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Pyke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raun</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;ffer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tang-Christensen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Witgen</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Vrang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bjerre Knudsen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.</article-title>
            <source>J Clin Invest</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>124</volume>
            <issue>10</issue>
            <fpage>4473</fpage>
            <page-range>4473-88</page-range>
            <pub-id pub-id-type="pmid">25202980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pi-Sunyer</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Astrup</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fujioka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Greenway</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Halpern</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krempf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>le Roux</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Violante Ortiz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Wilding</surname>
                <given-names>JP</given-names>
              </name>
              <collab>SCALE Obesity and Prediabetes NN8022-1839 Study Group</collab>
            </person-group>
            <article-title>A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Jul</month>
            <day>02</day>
            <volume>373</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-22</page-range>
            <pub-id pub-id-type="pmid">26132939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marso</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Brown-Frandsen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Nauck</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Ravn</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Stockner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bergenstal</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <collab>LEADER Steering Committee</collab>
              <collab>LEADER Trial Investigators</collab>
            </person-group>
            <article-title>Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Jul</month>
            <day>28</day>
            <volume>375</volume>
            <issue>4</issue>
            <fpage>311</fpage>
            <page-range>311-22</page-range>
            <pub-id pub-id-type="pmid">27295427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cusi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barb</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caprio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garvey</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mechanick</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Mouzaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nadolsky</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rinella</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Vos</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Younossi</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).</article-title>
            <source>Endocr Pract</source>
            <year>2022</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>528</fpage>
            <page-range>528-562</page-range>
            <pub-id pub-id-type="pmid">35569886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayendraraj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenkilde</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gasbjerg</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.</article-title>
            <source>Peptides</source>
            <year>2022</year>
            <month>May</month>
            <volume>151</volume>
            <fpage>170749</fpage>
            <pub-id pub-id-type="pmid">35065096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>GLP-1 receptor agonists: A review of glycemic benefits and beyond.</article-title>
            <source>JAAPA</source>
            <year>2024</year>
            <month>Apr</month>
            <day>01</day>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">38531038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nakata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Otgon-Uul</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yada</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>GLP-1 receptor agonist liraglutide exerts central action to induce &#x003b2;-cell proliferation through medulla to vagal pathway in mice.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>499</volume>
            <issue>3</issue>
            <fpage>618</fpage>
            <page-range>618-625</page-range>
            <pub-id pub-id-type="pmid">29601817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iepsen</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Lundgren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dirksen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Madsbad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Torekov</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.</article-title>
            <source>Int J Obes (Lond)</source>
            <year>2015</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>834</fpage>
            <page-range>834-41</page-range>
            <pub-id pub-id-type="pmid">25287751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farr</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Sofopoulos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsoukas</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dincer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Thakkar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sahin-Efe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Filippaios</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bowers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Srnka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gavrieli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Liakou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kanyuch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tseleni-Balafouta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mantzoros</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.</article-title>
            <source>Diabetologia</source>
            <year>2016</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>954</fpage>
            <page-range>954-65</page-range>
            <pub-id pub-id-type="pmid">26831302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damholt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Golor</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wierich</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ekblom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zdravkovic</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>635</fpage>
            <page-range>635-41</page-range>
            <pub-id pub-id-type="pmid">16707410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malm-Erjef&#x000e4;lt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bj&#x000f8;rnsdottir</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vanggaard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Helleberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Oosterhuis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van Lier</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Zdravkovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>1944</fpage>
            <page-range>1944-53</page-range>
            <pub-id pub-id-type="pmid">20709939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Younes</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Sasser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension.</article-title>
            <source>Am J Physiol Heart Circ Physiol</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>318</volume>
            <issue>1</issue>
            <fpage>H72</fpage>
            <page-range>H72-H77</page-range>
            <pub-id pub-id-type="pmid">31729903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association Professional Practice Committee</collab>
            <article-title>15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024.</article-title>
            <source>Diabetes Care</source>
            <year>2024</year>
            <month>Jan</month>
            <day>01</day>
            <volume>47</volume>
            <issue>Suppl 1</issue>
            <fpage>S282</fpage>
            <page-range>S282-S294</page-range>
            <pub-id pub-id-type="pmid">38078583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Liraglutide</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>1</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamborlane</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Barrientos-P&#x000e9;rez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fainberg</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Frimer-Larsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hafez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Jalaludin</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Kovarenko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Libman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shehadeh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weghuber</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>T</given-names>
              </name>
              <collab>Ellipse Trial Investigators</collab>
            </person-group>
            <article-title>Liraglutide in Children and Adolescents with Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Aug</month>
            <day>15</day>
            <volume>381</volume>
            <issue>7</issue>
            <fpage>637</fpage>
            <page-range>637-646</page-range>
            <pub-id pub-id-type="pmid">31034184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159959.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bjerre Knudsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Madsen</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Almholt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Drucker</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gotfredsen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Egerod</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Hegelund</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>M&#x000f8;lck</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Solberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thi</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Zdravkovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moerch</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.</article-title>
            <source>Endocrinology</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>151</volume>
            <issue>4</issue>
            <fpage>1473</fpage>
            <page-range>1473-86</page-range>
            <pub-id pub-id-type="pmid">20203154</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
